Cited by 322Psychedelics and Drug StudiesAlkaloids: synthesis and pharmacologySynthesis and bioactivity of alkaloids

The DOI matches its Crossref record; 102 of the 103 references it cites were found in a registry or an index.

Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.

McKenna, Dennis J·2004·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2004.03.002

Open this paper in CoChat — free account

Abstract

Ayahuasca is a hallucinogenic beverage that is prominent in the ethnomedicine and shamanism of indigenous Amazonian tribes. Its unique pharmacology depends on the oral activity of the hallucinogen, N,N-dimethyltryptamine (DMT), which results from inhibition of monoamine oxidase (MAO) by beta-carboline alkaloids. MAO is the enzyme that normally degrades DMT in the liver and gut. Ayahuasca has long been integrated into mestizo folk medicine in the northwest Amazon. In Brazil, it is used as a sacrament by several syncretic churches. Some of these organizations have incorporated in the United States. The recreational and religious use of ayahuasca in the United States, as well as "ayahuasca tourism" in the Amazon, is increasing. The current legal status of ayahuasca or its source plants in the United States is unclear, although DMT is a Schedule I controlled substance. One ayahuasca church has received favorable rulings in 2 federal courts in response to its petition to the Department of Justice for the right to use ayahuasca under the Religious Freedom Restoration Act. A biomedical study of one of the churches, the Uñiao do Vegetal (UDV), indicated that ayahuasca may have therapeutic applications for the treatment of alcoholism, substance abuse, and possibly other disorders. Clinical studies conducted in Spain have demonstrated that ayahuasca can be used safely in normal healthy adults, but have done little to clarify its potential therapeutic uses. Because of ayahuasca's ill-defined legal status and variable botanical and chemical composition, clinical investigations in the United States, ideally under an approved Investigational New Drug (IND) protocol, are complicated by both regulatory and methodological issues. This article provides an overview of ayahuasca and discusses some of the challenges that must be overcome before it can be clinically investigated in the United States.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2004.03.002

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Handbook of Psychopharmacology
Iversen, L. L., Iversen, S. D., & Snyder, S. H. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8 · Cited by 2,756
Serotonergic Studies in Patients With Affective and Personality Disorders
Coccaro, E. F. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810070013002 · Cited by 1,085
Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Evidence of linkage between the serotonin transporter and autistic disorder
Cook, E., Yeung-Courchesne, R., Lord, C., Cox, N. J., Yan, S., Lincoln, A. J., Haas, R., Courchesne, E., & LEVENTHAL, B. L. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000266 · Cited by 426
Hallucinogens and shamanism
Harner, M. J. (1973) · Oxford University Press eBooks · Cited by 406
Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of ayahuasca
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Self-citation
Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
The Human Platelet
Stahl, S. M. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770170019001 · Cited by 386
Amazonia 1492: Pristine Forest or Cultural Parkland?
Heckenberger, M. J., Kuikuro, A., Kuikuro, U. T., Russell, J. C., Schmidt, M., Fausto, C., & Franchetto, B. (2003) · Science · doi:10.1126/science.1086112 · Cited by 384

Flagged first, then by citations

Show all 103 references

1 of the 103 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

Airaksinen, 1981, β-Carbolines, psychoactive compounds in the mammalian body, Med Biol, 59, 21
Anonymous, 1855, Journal of a voyage up the Amazon and Rio Negro by Richard Spruce, San Carlos del Rio Negro, June 27, 1853, Hooker J Bot Kew Garden Misc, 6/7
Center for Cognitive Liberty and Ethics (2002a). Federal court rules in favor of ayahuasca-using church [Press release]. Available at: http://www.cognitiveliberty.org/dll/udv_pj_granted.htm.
Ho, 1979, Pharmacological and biochemical studies with β-carboline analogs, vol. 4, 215
Krajick, 1992, Vision quest, Newsweek, 44
Naranjo, 1986, El ayahuasca in la arqueologı́a ecuatoriana, Am Indig, 46, 117
Schultes, 1972, Ethnotoxocological significance of additives to New World hallucinogens, Plant Sci Bull, 18, 34
Topping, 1998, Ayahuasca and cancer: one man's experience, Bull Multidiscip Assoc Psychedelic Stud, 8, 22
Winkelman, 1995, Psychointegrator plants: their roles in human consciousness, cultures, and health, Yearb Cross-Cult Med Psychother, 9

Sorted by citations

Globalization and healthcare: understanding health and medical tourism
Carrera, P. M., & Bridges, J. F. P. (2006) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.6.4.447 · Cited by 434
β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)
Herraiz, T., González, D., Ancín-Azpilicueta, C., Arán, V. J., & Guillén, H. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.12.019 · Cited by 357
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study.
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F. D., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
The globalization of ayahuasca: harm reduction or benefit maximization?
Tupper, K. W. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.11.001 · Cited by 212
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 210
N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions
Shen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence
Sarris, J. J., McIntyre, E., & Camfield, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0059-9 · Cited by 157
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
Barker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142
Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca
Viol, A., Palhano-Fontes, F., Onias, H., de Araújo, D. B., & Viswanathan, G. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06854-0 · Cited by 141
A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.
Sklerov, J., Levine, B., Moore, K. A., King, T., & Fowler, D. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.838 · Cited by 144
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134
“P23229 ITGA6 21 (3) Integrin alpha-6 3.”
Influential
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 138
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca
SANTOS, R. G. D., Valle, M., Bouso, J. C., Nomdedeu, J. F., Rodrı́guez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 143
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Jarhad, D. B., Mashelkar, K. K., Kim, H., Noh, M., & Jeong, L. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00185 · Cited by 136
The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Penke, B., Fülöp, L., Szűcs, M., & Frecska, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170529104323 · Cited by 132
Toxicokinetics and Toxicodynamics of Ayahuasca alkaloids N,N-dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: clinical and forensic impact
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117
A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats
Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05817-8 · Cited by 112
Ayahuasca healing beyond the Amazon: the globalization of a traditional indigenous entheogenic practice
Tupper, K. W. (2008) · Global Networks · doi:10.1111/j.1471-0374.2009.00245.x · Cited by 112
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
A Deep-Dream Virtual Reality Platform for Studying Altered Perceptual Phenomenology
Suzuki, K., Roseboom, W., Schwartzman, D. J., & Seth, A. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16316-2 · Cited by 119
Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination.
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-61169-x · Cited by 110
Ayahuasca Tourism: Participants in Shamanic Rituals and their Personality Styles, Motivation, Benefits and Risks
Kavenská, V., & Simonová, H. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1094590 · Cited by 108
Psychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105
Ibogaine in the Treatment of Substance Dependence
Brown, T. (2013) · Current Drug Abuse Reviews · doi:10.2174/15672050113109990001 · Cited by 104
Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat
Pic‐Taylor, A., da Motta, L. G., de Morais, J. A., Melo, W., Santos, A. D. F. A., Campos, L. A., Mortari, M. R., von Zuben, M. V., & Caldas, E. D. (2015) · Behavioural Processes · doi:10.1016/j.beproc.2015.05.004 · Cited by 102
Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources
McClatchey, W. C., Mahady, G. B., Bennett, B. C., Shiels, L., & Savo, V. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.002 · Cited by 100
Experiences of encounters with Ayahuasca–“the vine of the soul”
Kjellgren, A., Eriksson, A., & Norlander, T. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10399767 · Cited by 97
“Plantas con madre”: Plants that teach and guide in the shamanic initiation process in the East-Central Peruvian Amazon
Jauregui, X., Clavo, Z. M., Jovel, E. M., & Pardo‐de‐Santayana, M. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.01.042 · Cited by 95
“Research Chemicals”: Tryptamine and Phenethylamine Use Among High-Risk Youth
Sanders, B., Lankenau, S. E., Bloom, J. J., & Hathazi, D. (2008) · Substance Use & Misuse · doi:10.1080/00952990701202970 · Cited by 92
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
Lawn, W., Hallak, J. E. C., Crippa, J. A. S., SANTOS, R. G. D., Porffy, L., Barratt, M. J., Ferris, J., WINSTOCK, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 83
Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey
Perkins, D., Schubert, V., Šimonová, H., Tófoli, L. F., Bouso, J. C., Horák, M., Coelho, N. L. G., & Sarris, J. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623979 · Cited by 77
Various Alkaloid Profiles in Decoctions of Banisteriopsis Caapi
Callaway, J. C. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399796 · Cited by 77
Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Gas chromatographic analysis of dimethyltryptamine and β‐carboline alkaloids in ayahuasca, an amazonian psychoactive plant beverage
Pires, A. P. S., de Oliveira, C. D. R., Moura, S., Dörr, F. A., Silva, W. A. E., & Yonamine, M. (2009) · Phytochemical Analysis · doi:10.1002/pca.1110 · Cited by 79
Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users
Cakic, V., Potkonyak, J., & Marshall, A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.015 · Cited by 72
The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs
Riga, M. S., Sòria, G., Tudela, R., Artigas, F., & Celada, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000261 · Cited by 76
Short-Term Treatment Effects of a Substance Use Disorder Therapy Involving Traditional Amazonian Medicine
Berlowitz, I., Walt, H., Ghasarian, C., Mendive, F., & Martin-Soelch, C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1607956 · Cited by 72
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 78
Untitled work
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., Kornhuber, J., Quednow, B. B., & Müller, C. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00152 · Cited by 73
Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease
Katchborian-Neto, A., Santos, W. T., Nicácio, K. J., Corrêa, J. O. A., Murgu, M., Martins, T. M. M., Gomes, D. A., Goes, A. M., Soares, M. G., Dias, D. F., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112743 · Cited by 62
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions
Yu, A. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9028-5 · Cited by 60
Chemical composition of traditional and analog Ayahuasca
Kaasik, H., Souza, R. C. Z., Zandonadi, F. S., Tófoli, L. F., & Sussulini, A. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1815911 · Cited by 59
Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography–electrospray ionization-tandem mass spectrometry
McIlhenny, E. H., Pipkin, K. E., Standish, L. J., Wechkin, H. A., Strassman, R. J., & Barker, S. A. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.10.088 · Cited by 58
Connecting the Spiritual and Emotional Intelligences: Confirming an Intelligence Criterion and Assessing the Role of Empathy
King, D. B., Mara, C. A., & DeCicco, T. L. (2012) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2012.31.1.11 · Cited by 66
Modulatory effects of ayahuasca on personality structure in a traditional framework
Netzband, N., Ruffell, S., Linton, S., Tsang, W., & Wolff, T. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05601-0 · Cited by 56
Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58
Methodology for determining major constituents of ayahuasca and their metabolites in blood
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1657 · Cited by 59
Ayahuasca: Uses, Phytochemical and Biological Activities
Estrella-Parra, E. A., Almanza-Pérez, J. C., & Alarcón-Aguilar, F. J. (2019) · Natural Products and Bioprospecting · doi:10.1007/s13659-019-0210-5 · Cited by 61
Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study
Perkins, D., Pagni, B. A., Sarris, J. J., Barbosa, P. C. R., & Chenhall, R. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884703 · Cited by 63
Psychedelic Moral Enhancement
Earp, B. D. (2018) · Royal Institute of Philosophy Supplement · doi:10.1017/s1358246118000474 · Cited by 55
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Lowe, H. I. C., Toyang, N. J., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. F. (2022) · Molecules · doi:10.3390/molecules27082520 · Cited by 58
The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.049 · Cited by 50
Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?
Lanaro, R., Calemi, D. B. D. A., Togni, L. R., Costa, J. L., Yonamine, M., Cazenave, S. O. S., & Linardi, A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1013202 · Cited by 52
Identification of N,N‐dimethyltryptamine and β‐carbolines in psychotropic ayahuasca beverage
Gambelunghe, C., Aroni, K., Rossi, R., Moretti, L. D., & Bacci, M. (2008) · Biomedical Chromatography · doi:10.1002/bmc.1023 · Cited by 55
Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2010) · Biomedical Chromatography · doi:10.1002/bmc.1551 · Cited by 53
Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Cata-Preta, E. G., Serra, Y. A., Moreira-Junior, E. D. C., Reis, H. S., Kisaki, N. D., Libarino-Santos, M., Silva, R. R. R., Barros-Santos, T., Santos, L. C., Barbosa, P. C. R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00561 · Cited by 53
An introduction to psychedelic neuroscience
Calvey, T., & Howells, F. M. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.013 · Cited by 57
Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model
Wu, C., Jiang, X.-L., Shen, H.-W., & Yu, A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.011 · Cited by 50
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew
Tupper, K. W., & Labate, B. C. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107155042 · Cited by 48
The health impact of tourism on local and indigenous populations in resource-poor countries
Bauer, I. L. (2008) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2008.05.005 · Cited by 47
Analytical chemistry of synthetic routes to psychoactive tryptamines : Part II. Characterisation of the Speeter and Anthony synthetic route to N,N-dialkylated tryptamines using GC-EI-ITMS, ESI-TQ-MS-MS and NMR
Brandt, S. D., Freeman, S., Fleet, I. A., McGagh, P., & Alder, J. F. (2005) · The Analyst · doi:10.1039/b413014f · Cited by 46
Forbidden Therapies: Santo Daime, Ayahuasca, and the Prohibition of Entheogens in Western Society
Blainey, M. G. (2014) · Journal of Religion and Health · doi:10.1007/s10943-014-9826-2 · Cited by 45
Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
Szmulewicz, A., Valerio, M. P., & Smith, J. M. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0020-y · Cited by 45
“Tobacco Is the Chief Medicinal Plant in My Work”: Therapeutic Uses of Tobacco in Peruvian Amazonian Medicine Exemplified by the Work of a Maestro Tabaquero
Berlowitz, I., Torres, E. G., Walt, H., Wolf, U., Maake, C., & Martin-Söelch, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594591 · Cited by 43
Maternal and developmental toxicity of ayahuasca in Wistar rats
de Oliveira, C. D. R., Moreira, C. Q., de Sá, L. R. M., Spinosa, H. D. S., & Yonamine, M. (2010) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20244 · Cited by 44
Abuse Liability Profile of Three Substituted Tryptamines
Gatch, M. B., Forster, M. J., Janowsky, A. J., & Eshleman, A. J. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179705 · Cited by 43
Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors
Drung, B., Scholz, C., Barbosa, V. A., Nazari, A., Sarragiotto, M. H., & Schmidt, B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.054 · Cited by 41
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
Ayahuasca as a Candidate Therapy for PTSD
Nielson, J. L., & Megler, J. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_3 · Cited by 40
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
Shen, H.-W., Wu, C., Jiang, X.-L., & Yu, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.02.020 · Cited by 40
Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Savoldi, R., Polari, D., Pinheiro‐da‐Silva, J., Silva, P. F., Soares, B. L., Yonamine, M., Freire, F. A. D. M., & Luchiari, A. C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00139 · Cited by 39
Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology
Luke, D. P. (2011) · Greenwich Academic Literature Archive (University of Greenwich) · Cited by 40
Psychoactive Substances and Paranormal Phenomena: A Comprehensive Review
Luke, D. P. (2012) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2012.31.1.97 · Cited by 42
Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats
Gatch, M. B., Rutledge, M. A., Carbonaro, T. M., & Forster, M. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1501-z · Cited by 40
Conceptions and practices of an integrative treatment for substance use disorders involving Amazonian medicine: traditional healers’ perspectives
Berlowitz, I., Ghasarian, C., Walt, H., Mendive, F. M., Alvarado, V., & Martin-Söelch, C. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2016-2117 · Cited by 48
Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review
Simão, A. Y., Gonçalves, J., Duarte, A. P., Barroso, M., Cristóvão, A. C., & Gallardo, E. (2019) · Medicines · doi:10.3390/medicines6040106 · Cited by 45
The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription
Onishi, Y., Oishi, K., Kawano, Y., & Yamazaki, Y. (2011) · Bioscience Reports · doi:10.1042/bsr20110002 · Cited by 38
Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine
Dean, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00232 · Cited by 37
Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples
Silveira, G. D. O., SANTOS, R. G. D., Lourenço, F. R., Rossi, G. N., Hallak, J. E. C., & Yonamine, M. (2020) · Molecules · doi:10.3390/molecules25092072 · Cited by 37
The therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 37
Phenomenology of N,N-Dimethyltryptamine use : a thematic analysis
Cott, C., & Rock, A. J. (2008) · Journal of Scientific Exploration · Cited by 37
Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats
Favaro, V. M., Yonamine, M., Soares, J. C. K., & Oliveira, M. G. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145840 · Cited by 36
Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 37
Trends in DMT and other tryptamine use among young adults in the United States
Palamar, J. J., & Le, A. (2018) · American Journal on Addictions · doi:10.1111/ajad.12803 · Cited by 35

Authors: McKenna, D. J.
Affiliations: University of Minnesota (US)
Corresponding author: McKenna, Dennis J
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2004-05
Volume: 102
Issue: 2
Pages: 111-129
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2004.03.002
OpenAlex: W2161026846
Cited by: 321
References: 103
Citations by year: 2026: 7 · 2025: 11 · 2024: 16 · 2023: 9 · 2022: 23 · 2021: 17 · 2020: 33 · 2019: 12 · 2018: 22 · 2017: 15 · 2016: 19 · 2015: 18 · 2014: 15 · 2013: 12 · 2012: 20
FWCI: 0.85
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
Physical Sciences › Chemistry › Organic Chemistry › Synthesis and bioactivity of alkaloids
Keywords: ayahuasca, N,N-dimethyltryptamine, monoamine oxidase inhibition, β-carbolines, ayahuasca tourism, Religious Freedom Restoration Act, União do Vegetal, alcoholism treatment, addiction treatment, clinical research regulation, Schedule I controlled substances, hallucinogens
MeSH terms: Brazil, Clinical Trials as Topic, N,N-Dimethyltryptamine, Humans, Legislation, Drug, Phytotherapy, Plant Extracts, Psychotropic Drugs, United States, United States Food and Drug Administration, Molecular Structure, Banisteriopsis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks